2018 Annual Performance Pre-increase Announcement
Release time:
2020-08-05
Securities Code: 600668 Securities Abbreviation: Jianfeng Group Announcement No.: Pro 2019-003
Bond Abbreviation: 13 Peak 02 Bond Code: 122344
Zhejiang Jianfeng Group Co., Ltd.
2018 Annual Performance Pre-increase Announcement
The Board of Directors and all directors of the Company guarantee that there are no false records, misleading statements or major omissions in the contents of this announcement, and shall bear individual and joint liabilities for the authenticity, accuracy and completeness of its contents.
Important Content Note:
L Company expects to realize net profit attributable to shareholders of listed companies in 2018 to increase by 20 , 212 yuan to 27 , 182 yuan, up 58% to 78% year on year.
l expects the net profit attributable to shareholders of listed companies after deducting non-recurring gains and losses in 2018 to increase by 18 , 042 yuan to 24 , 724 yuan, up 54% to 74% year on year.
1. Current Performance Forecast
(I) Performance Forecast Period
2018 January 1 to December 31, 2018.
(II) Performance Forecast
1. According to preliminary calculations by the financial department, the net profit attributable to shareholders of listed companies is expected to increase by 202.12 million yuan to 271.82 million yuan in 2018 compared with the same period last year, an increase of 58% to 78% year on year.
2. It is estimated that the net profit after deducting non-recurring gains and losses attributable to shareholders of listed companies in 2018 will increase by 18 , 042 yuan to 24 , 724 yuan, up 54% to 74% year on year.
(III)'s current performance forecast is the company's preliminary budget based on operating conditions and has not been audited by a certified public accountant.
2.'s performance in the same period last year
(I) net profit attributable to shareholders of listed companies: 34,849.43 yuan; Net profit attributable to shareholders of listed companies after deducting non-recurring gains and losses: 334.1121 million yuan.
(II) earnings per share: 1.01 yuan.
3. the main reason for the pre-increase in the current performance
The main reason for the company's performance growth during the reporting period: On the one hand, benefiting from the phased results of the country's "supply-side structural reform", the cement industry The market supply-demand relationship has improved, and the company's cement product prices have increased significantly year-on-year; on the other hand, company's cement business has always adhered to the cost leadership strategy, continuously strengthen management and process innovation, cost control achieved better results .
4. Risk Warning
The above forecast data include the investment income of Tianshili Holding Group Co., Ltd., Zhejiang Nanfang Jianfeng Cement Co., Ltd. and other joint venture (equity method accounting) equity , but its financial report has not been audited at present, is not yet able to accurately determine the performance data of these joint venture enterprises 2018 . There is a certain degree of uncertainty in the accuracy of the company's current performance forecast, which may differ from the company's final audited performance data. The Company will continue to pay attention to the impact of investment income on actual performance and fulfill its information disclosure obligations as required.
In addition, the company does not have any other major uncertainties affecting the accuracy of the performance forecast.
Other 5. Notes
The above forecast data are only preliminary accounting data. The specific and accurate financial data shall be subject to the audited annual report of 2018 officially disclosed by the company. Please pay attention to the investment risks.
is hereby announced.
Zhejiang Jianfeng Group Co., Ltd.
Board of Directors
January 28, 2019
More information
Publicity of Environmental Protection Acceptance for Completion of Kiln End Flue Gas Desulfurization Project of daye peak cement co., ltd. According to the requirements of the Interim Measures for Environmental Protection Acceptance for Completion of Construction Projects (No.4 [2017] of the State Environmental Regulations) issued by the Ministry of Environmental Protection, the environmental protection acceptance information of "Kiln End Flue Gas Desulfurization Project" of daye peak cement co., ltd. is now publicized. Basic Information of 1. Project Project Name: Kiln End Flue Gas Desulfurization Project Construction Unit: daye Jianfeng Cement Co., Ltd. Project Construction Location: Yongguang Village, Baoan Town, daye city, nature of the project in the existing plant area of daye Jianfeng Cement Co., Ltd.: The construction content of the technological transformation project is: This technological transformation project is mainly to build a wet desulfurization system for kiln end gas of the company's existing 4000t cement clinker production line, adopting limestone-gypsum wet flue gas desulfurization process. The project covers a total area of 500 m2, with a new construction area of about 450 m2. It mainly builds desulfurization complex building, flue gas system, SO2 absorption system, limestone powder conveying and limestone slurry preparation system, process water system, gypsum dehydration system and supporting pipelines. Power supply, water supply, compressed air and other public works rely on the existing plant. Total investment and environmental protection investment: the total investment of the project is 10.37 million yuan, all of which are environmental protection investment. The project was entrusted to Huangshi Yangtze River Environmental Engineering Design and Research Institute to carry out environmental impact assessment in September 2017. On November 16, 2017, Daye Municipal Environmental Protection Bureau issued a reply with YEHAN [2017] No. 354. Implementation of 2. environmental protection measures The scope of this acceptance is the flue gas desulfurization system and supporting facilities at the end of the kiln. (1) Exhaust gas pollution
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Contact Us
No. 88 Wujiang East Road, Jinhua City, Zhejiang Province, China
Tel: +86-579-82326868
Fax : +86-579-82324666
©2023 Zhejiang Jianfeng Group Co., Ltd. Powered by: www.300.cn SEO Business License
SAF Coolest v1.2 设置面板 SHJSS-AHDB-FSSQE-ZSW
无数据提示
Sorry, the current column has no content !
You can view other columns or return to Home Page